CytoMed Therapeutics Ltd (GDTC) News

CytoMed Therapeutics completes cash acquisition of Cord Blood Banking Licence and Assets expanding CytoMed’s strategy to cord blood-derived biologics through subsidiary, LongevityBank

SINGAPORE, Oct. 03, 2024 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

CytoMed Therapeutics Reports Six Months Ended June 30, 2024 Financial Results and Provides Clinical and Corporate Updates

Conference call via Zoom is scheduled for October 8, 2024 at 9 a.m. ET (9 p.m. SGT) https://us06web.zoom.us/mee...

CytoMed Therapeutics Acquires Cord Blood Banking Licence and Assets to Entrench Its Strategy in Allogeneic, Off-the-shelf Donor-derived Gamma Delta (γδ) T Cells Technology for Solid and Liquid Cancers

SINGAPORE, July 17, 2024 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

CytoMed Therapeutics to Launch Complimentary Cell Banking for Qualified Shareholders for Future Precision Therapies

SINGAPORE, March 18, 2024 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or...

CytoMed Therapeutics Limited Announces Research Collaboration with Singapore Sengkang General Hospital to Advance Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Diseases and Repair

SINGAPORE, March 04, 2024 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or...

Malaysian Patent Granted for CytoMed Therapeutics' Licensed Allogeneic CAR-Gamma Delta T Cell Technology

SINGAPORE, Jan. 29, 2024 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or...

CytoMed Therapeutics Signs HOA and MOU to Advance Research on Allogeneic Gamma Delta T Cell Technology

CytoMed Therapeutics Signs HOA and MOU to Advance Research on Allogeneic Gamma Delta T Cell Technology PR...

CytoMed Therapeutics Reports First Half 2023 Financial Report and Provides Corporate Update

CytoMed Therapeutics Reports First Half 2023 Financial Report and Provides Corporate Update PR...

CytoMed Therapeutics to Present at The Benchmark Company's Upcoming Discovery One-on-One Investor Conference

CytoMed Therapeutics to Present at The Benchmark Company's Upcoming Discovery One-on-One Investor...

Chinese Patent Granted for CytoMed Therapeutics' Licensed iPSC-Based Technology

Chinese Patent Granted for CytoMed Therapeutics' Licensed iPSC-Based Technology PR Newswire SINGAPORE, Sept...

CytoMed Therapeutics Announces China Research Collaboration to Enhance its Allogeneic CAR γδ T In Vivo Persistency

CytoMed Therapeutics Announces China Research Collaboration to Enhance its Allogeneic CAR γδ T In Vivo...